Results 121 to 130 of about 96,094 (164)
Some of the next articles are maybe not open access.
2015
Cancer is a complex disease that results from the successive accumulation of genetic and epigenetic alterations. These, together with transcriptional deregulation, and aberrations in post-translational modification, are the forces driving carcinogenesis.
Junhui Wang +4 more
openaire +1 more source
Cancer is a complex disease that results from the successive accumulation of genetic and epigenetic alterations. These, together with transcriptional deregulation, and aberrations in post-translational modification, are the forces driving carcinogenesis.
Junhui Wang +4 more
openaire +1 more source
PARP and Epigenetic Regulation
2008In the post-genome era attention is being focused on those epigenetic modifications which modulate chromatin structure to guarantee that information present on DNA is read correctly and at the most appropriate time in order to meet cellular requirements.
openaire +2 more sources
Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors
Drug Discovery Today: Disease Models, 2012PARP-1 protects cells from endogenous and therapeutically inflicted DNA damage. PARP inhibitors have been under development since 1980 and first entered clinical trial in 2003. They are an exciting new class of drugs that have the potential to increase the efficacy of anticancer DNA damaging agents and to selectively target cells that have defects in ...
openaire +2 more sources
Science, 2003
The enzyme PARP is ubiquitous among eukaryotes (except for budding yeast) and is known to be important for repairing damaged DNA. In his Perspective, [Pirrotta][1] unveils a new job for this versatile polymerase. PARP turns out to be important for the formation of puffs in the giant chromosomes of Drosophila ([Tulin and Spradling][2]).
openaire +1 more source
The enzyme PARP is ubiquitous among eukaryotes (except for budding yeast) and is known to be important for repairing damaged DNA. In his Perspective, [Pirrotta][1] unveils a new job for this versatile polymerase. PARP turns out to be important for the formation of puffs in the giant chromosomes of Drosophila ([Tulin and Spradling][2]).
openaire +1 more source
IDrugs : the investigational drugs journal, 2005
Poly(ADP-ribose) polymerase (PARP) catalyzes the biochemical conversion of nicotinamide adenine dinucleotide (NAD+) to poly(ADP-ribose) and nicotinamide, which is a weak feedback inhibitor of the enzyme. Early designs of PARP inhibitors were primarily based on mimicking the structure of nicotinamide and resulted in the identification and widespread use
J H, Li, J, Zhang
openaire +3 more sources
Poly(ADP-ribose) polymerase (PARP) catalyzes the biochemical conversion of nicotinamide adenine dinucleotide (NAD+) to poly(ADP-ribose) and nicotinamide, which is a weak feedback inhibitor of the enzyme. Early designs of PARP inhibitors were primarily based on mimicking the structure of nicotinamide and resulted in the identification and widespread use
J H, Li, J, Zhang
openaire +3 more sources
Proceedings of the National Academy of Sciences of the United States of America, 2021
John Lydon +2 more
exaly
John Lydon +2 more
exaly
2016
Inhibition of Poly (ADP-ribose) polymerase 1 has relatively recently entered the clinic. The ground-breaking drug both scientifi cally and clinically was olaparib, but several other PARP inhibitors are in development. This treatment is the fi rst to therapeutically exploit mutant recessive cancer genes.
Grève, J.De +8 more
openaire +1 more source
Inhibition of Poly (ADP-ribose) polymerase 1 has relatively recently entered the clinic. The ground-breaking drug both scientifi cally and clinically was olaparib, but several other PARP inhibitors are in development. This treatment is the fi rst to therapeutically exploit mutant recessive cancer genes.
Grève, J.De +8 more
openaire +1 more source